Welcoming Our Newest Executive Committee Member

March 22, 2022 

“The use of technology in women’s health is a rapidly evolving space, yet more must be done to create greater impact,”

New York, NY, March 18, 2022 — HITLAB is pleased to announce that Rachel Stahler, CIO of Organon, has joined the executive committee of the Women’s Health Tech Initiative (WHTI). Organon is a global healthcare company formed through a spinoff from Merck & Co. with a vision to create a better and healthier every day for every woman around the globe.

HITLAB’s Women’s Health Tech Initiative was founded in 2018 with the mission of addressing the unmet health needs of women globally and increasing gender equity in technology and venture. 

The Executive Committee is a group of passionate and experienced volunteers who share the collective goal of improving women’s health outcomes worldwide. Ms. Stahler and Organon will join a distinguished team including Chair Priscilla Beal of Bayer, Vanessa Liu of SAP, Prem Tumkosit of Merck Global Health Innovation Fund, Kris Brown of Goodwin, and Amy West of Novo Nordisk.

The WHTI Executive Committee meets every quarter to ensure that the strategy and tactics of the organization align with the needs of the women’s health tech community locally, nationally, and globally. Members provide feedback and strategic direction to the WHTI Team and the charter is updated and renewed as necessary. 

The use of technology in women’s health is a rapidly evolving space, yet more must be done to create greater impact,” Organon’s Rachel Stahler said. “I look forward to joining the Women’s Health Tech Initiative Executive Committee to help foster new technologies and innovation that address the unmet health needs of women worldwide.” 

 “We are proud to add Rachel and Organon to our team of Women’s Health Tech Visionaries. We are confident she will serve as a tremendous benefit to our cohort of innovators,” said Sara Chokshi Susan Solinsky, Director of HITLAB Research Practice and Member of WHTI Board. “We are excited to have her share her vision, expertise and guidance to help drive the future development of Innovative digital health technologies that can meet the healthcare needs of women globally.” 

About HITLAB

Established in 1998, HITLAB is a leading evidence-based, digital health efficacy teaching and testing center specializing in the delivery of world-class digital health innovation research. We help leading organizations ideate, create, and evaluate technology-based solutions to pressing healthcare challenges across the globe. HITLAB works with a wide variety of stakeholders in both the public and private sectors to design and disseminate studies, programs, and products that improve healthcare access and delivery. 

Explore Recent Posts

ADHD in the U.S.: Tackling Diagnosis & Treatment Gaps with Technology

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition affecting millions of people in the United States. Approximately 7 million (11.4%) U.S. children aged 3–17 years have ever been diagnosed with ADHD, according to a national survey of parents using data from 2022.

Explore Recent Posts

ADHD in the U.S.: Tackling Diagnosis & Treatment Gaps with Technology

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition affecting millions of people in the United States. Approximately 7 million (11.4%) U.S. children aged 3–17 years have ever been diagnosed with ADHD, according to a national survey of parents using data from 2022.